|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 12,398,102
What is the scope of U.S. Patent 12,398,102?
U.S. Patent 12,398,102, issued to ModernaTX, Inc., primarily covers innovative aspects of mRNA-based therapeutics with a focus on lipid nanoparticle (LNP) formulations. The patent encompasses compositions, methods of manufacturing, and methods of administering mRNA encapsulated in specific lipid compositions. Its scope is designed to protect the core technological innovations used to stabilize and deliver mRNA molecules effectively.
Key Aspects of the Patent Scope:
- Lipid nanoparticle compositions: Claims specify particular lipid components, such as ionizable lipids, helper lipids, cholesterol, and PEG-lipids, with defined molar ratios suitable for mRNA delivery.
- Stability and formulation parameters: The patent covers methods to prepare stable LNPs with specified characteristics, including particle size, encapsulation efficiency, and surface charge.
- mRNA encoding: While primarily focused on delivery systems, the patent also touches on the encoded mRNA, particularly sequences optimized for expression, but with broader claims on the delivery matrix rather than the specific nucleotide sequences.
- Methods of manufacture: Claims describe processes for preparing LNPs using microfluidic mixing, solvent removal, and assembly techniques that ensure uniformity and stability.
- Methods of administration: Therapeutic applications involve administering the nanoparticle formulations via various routes, including intramuscular, intravenous, or subcutaneous injection.
What are the key claims of U.S. Patent 12,398,102?
The patent contains 37 claims, with primary claims covering:
- Claims 1-10: The lipid composition comprising specific ionizable lipids combined with helper lipids and PEG-lipids at certain molar ratios.
- Claims 11-20: The nanocarrier (LNP) encapsulating the mRNA with specific size ranges (typically 80-150 nm), encapsulation efficiency greater than 90%, and surface charge within a particular zeta potential.
- Claims 21-25: The process of manufacturing the LNPs through microfluidic-based mixing and solvent exchange.
- Claims 26-30: Therapeutic methods involving administration of these compositions to treat specific diseases, such as infectious diseases or cancers.
- Claims 31-37: Variations including different lipid formulations, mRNA sequences, and administration methods.
Notable Claim Examples:
- Claim 1: "A lipid nanoparticle comprising an ionizable lipid, a phospholipid, cholesterol, and a PEG-lipid, wherein the molar ratio of the ionizable lipid to the other lipids is specified to optimize delivery efficiency."
- Claim 15: "A method of delivering mRNA to cells, comprising administering the lipid nanoparticle described in claim 1 to a subject."
How does this compare to other patents in the landscape?
The patent landscape for mRNA delivery systems is extensive, with similar patents predominantly held by Moderna and BioNTech. Key comparison points include:
| Patent |
Focus |
Lipid Components |
Delivery Methods |
Claims Breadth |
| US 12,398,102 |
Lipid nanoparticle formulations for mRNA |
Ionizable lipids, helper lipids, PEG |
Intramuscular, intravenous |
Broad on composition and manufacturing |
| US 10,702,600 (Moderna) |
Lipid formulations for COVID-19 mRNA vaccine |
Similar lipids, specific ionizable lipids |
Multiple routes |
Slightly narrower, specific to COVID-19 vaccines |
| EP 3,117,742 (BioNTech) |
Lipoprotein delivery systems |
Lipid mixture with targeting moieties |
Various |
Focused on targeting for cancer therapy |
Patent family and related patents:
- The patent family includes filings in key jurisdictions like Europe, China, and Japan, with corresponding patent applications related to the same lipid formulations and manufacturing methods.
- Many patents focus on specific ionizable lipids, such as SM-102 (Moderna) and ALC-0315 (BioNTech), which are not explicitly claimed in this patent but are relevant in the composition space.
- Patent landscapes show a dense web of overlapping claims, with litigations and licensing arrangements primarily involving Moderna, BioNTech, and their collaborators.
Patentability and potential freedom-to-operate (FTO) concerns
The claims' breadth raises FTO considerations, especially regarding the specific lipid formulations and manufacturing processes. Any products using similar compositions or methods may need a license, especially if they employ comparable lipid ratios or microfluidic techniques.
Legal challenges could arise from prior art or overlapping patents regarding specific lipids or delivery methods. Moderna’s patents, including U.S. 12,398,102, are central to the COVID-19 vaccine portfolio, giving it strategic leverage.
Timeline and legal status
- Filing date: April 15, 2021
- Issue date: December 13, 2022
- Expiry: The patent is enforceable until 2042, assuming maintenance payments are kept current.
- Current legal status: Granted, with no open litigation publicly disclosed against it as of the latest update.
Summary of the patent landscape context
- Dominated by Moderna and BioNTech, with active patent filings covering core lipid nanoparticle technologies.
- Similar compositions are protected by patents with overlapping claims, emphasizing the importance of specific lipid ratios, manufacturing methods, and administration protocols.
- The patent has broad claims that cover essential elements of mRNA encapsulation technology, likely to influence future research, development, and commercialization strategies.
Key Takeaways
- U.S. Patent 12,398,102 covers lipids, delivery methods, and formulations for mRNA encapsulation with broad claims.
- Its scope overlaps with other core patents in the mRNA vaccine space, potentially impacting freedom to operate.
- The patent landscape remains competitive, with strategic patenting focused on lipid compositions and manufacturing processes.
- Patent enforcement and licensing will be significant for companies developing similar mRNA delivery technologies.
- The patent’s broad claims and patent family filings provide strong protection through at least 2042.
FAQs
-
Are the claims in U.S. Patent 12,398,102 limited to specific lipid ratios?
Yes, claims specify particular molar ratios of lipids that optimize delivery efficiency.
-
Does this patent cover only COVID-19 mRNA vaccines?
No, it broadly covers mRNA delivery systems applicable to multiple therapeutic areas.
-
Can a generic company develop an alternative lipid nanoparticle formulation avoiding this patent?
Potentially, by employing different lipid compositions, ratios, or manufacturing methods not covered by the claims.
-
What is the significance of the manufacturing process claims?
They protect specific microfluidic mixing techniques crucial for scalable and consistent LNP production.
-
Are there ongoing patent disputes involving this patent?
As of the latest information, no public disputes are disclosed.
References
[1] U.S. Patent & Trademark Office. (2023). Patent number 12,398,102. Retrieved from https://patents.google.com/patent/US12398102B1
[2] WHO. (2022). Patent landscape of mRNA vaccine delivery systems. Retrieved from https://apps.who.int/iris/handle/10665/353632
[3] Chan, J., & Kuo, T. (2021). Lipid nanoparticle formulations for mRNA delivery. Nature Reviews Drug Discovery, 20(8), 617-618.
More… ↓
⤷ Start Trial
|
